
WFH, Sanofi and Sobi for Armenia: Unprecedented Commitment to Build the Humanitarian Aid Program
Scott Williams, VP and Head, Global Public Affairs at Sanofi, shared an honoring post on LinkedIn:
”In 2014, the World Federation of Hemophilia (WFH) put out a call to action to join them and build their Humanitarian Aid (HA) Program into a more sustainable and predictable solution. Sanofi, along with Sobi, responded with an unprecedented commitment – to provide 1 billion IUs of factor therapy over 10 years. This commitment drove other companies to collaborate with the WFH HA Program and together, we empowered the WFH to provide treatment not only for life-saving surgeries but also for acute bleeds and prophylaxis in children.
I have just returned from a Humanitarian Aid visit with the World Federation of Hemophilia to Armenia. It is with humility that I share a look into 5 extraordinary days together.
It was so impactful to see the before and after progress that’s been made over the past 10+ years in Armenia. We saw a strong hemophilia treatment center and integrated multi-disciplinary care team, access to factor therapy, ability to have prophylaxis treatment at home, impactful local patient organization (NMO), and more. Meeting and hearing the stories of patients and families whose lives have been forever transformed truly puts the “human” in the humanitarian program. It is a powerful reminder of the good that can be achieved when we work together with a shared purpose.
At Sanofi, we are working as a committed industry partner with stakeholders across the bleeding disorders community to drive forward comprehensive, patient-centric solutions that go Beyond the Bleed to meaningfully advance the care paradigm. Envisioning a future beyond the bleed lies at the heart of our mission.
I will never be the same after the visit to Armenia with the WFH. The tears, hope, smiles, determination, and perseverance of children and family members living with hemophilia ensured that I will continue to be a deeply committed Rare Ambassador.”
More encouraging stories featured in Hemostasis Today.
-
Jul 27, 2025, 06:41Clot Classroom: Meaningful Insights into Renal Vein Thrombosis Awareness
-
Jul 27, 2025, 06:04Unlocking Hematology: Dr. Houssein Safa’s Game-Changing Educational Series for Internists
-
Jul 26, 2025, 18:32From Jawless Fish to Mammals: Clotting Cascade Origins
-
Jul 26, 2025, 15:12ISTH 2025 Guidelines: Submit Your Topic Proposals by September 8
-
Jul 26, 2025, 15:05Beyond the Needle: The BUTTERFLY Study Eases LMWH Burden
-
Jul 27, 2025, 16:22WSO Global Stroke Fact Sheet 2025: A Sobering Reminder
-
Jul 27, 2025, 12:14Villalta Score in Review: Improving PTS Assessment Through Clinical Criteria
-
Jul 27, 2025, 06:16Can a Single DNA Change Decide If You’ll Have a Boy or a Girl? Scientists Think So
-
Jul 26, 2025, 18:21C-Terminal VWF Variants in von Willebrand Disease: Functional Insights from the D4-C6 Domains
-
Jul 26, 2025, 17:271 Hypothesis, Multiple Implications: Adenoviral Vector Vaccines and Thrombosis with Thrombocytopenia Syndrome
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 26, 2025, 16:14Cesar Garrido: Forging Strong Partnerships on WHA78 ''Global Health Equity'' Event
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders
-
Jul 23, 2025, 10:43From Blood Clot Survivor to NFL History: Trey Smith’s Record Deal
-
Jul 22, 2025, 16:48How Children See Blood Clots: World Thrombosis Day Shares Artwork from Young Artists